Abandoned a $134 million advance payment for AbbVie to terminate two antibody research and development partnerships.

Guide: Voyager Therapeutics' collaboration with AbbVie's tau protein and alpha-synaptic nucleoprotein vector antibodies has been terminated. On August 3,
, Voyager Therapeutics announced that its cooperation with AbbVie's tau protein and alpha-synaptic nucleoprotein vector antibodies had been terminated (for an undisclosed reason).
Voyager will retain the full rights of vectorization technology and the co-developed new vector expression antibody.
, Voyager's shares fell 12 per cent in pre-market trading and continued to fall nearly 9 per cent in early trading as a result of the break-up of the partnership.
2018, Voyager and AbbVie signed the first strategic agreement to jointly develop and commercialize vector antibodies against tau proteins.
Tau protein pathology became a hot spot after multiple setbacks of amyloid beta protein.
in Alzheimer's patients, abnormal tau protein tangles generally occur at the end of the disease and are associated with degenerative neurodegenerative changes and severity. The
partnership aims to develop a potential one-time treatment that uses Voyager's gene therapy platform to produce adenovirus (AAV) vectors.
AbbVie paid Voyager $69 million in advance, under which the latter also had the opportunity to receive $155 million in pre-clinical and first-stage payments, and $895 million in development and regulatory milestone payments.
2019, Voyager and AbbVie expanded their collaboration to develop vector expression antibodies for pathological types of alpha-synaptic nucleoproteins for the treatment of Parkinson's disease and other diseases characterized by abnormal accumulation of misfolded alpha-synaptic nucleoproteins.
in this partnership, AbbVie paid $65 million in advance, Voyager had the opportunity to receive $245 million in pre-clinical and first phase payments, $728 million in development and regulatory milestones, and $500 million in commercial milestone payments.
two co-op deals worth more than $2.6 billion, and AbbVie has so far put in more than $134 million in advances.
with the end of the partnership, Voyager has resumed all clinical development and commercialization rights for certain candidate products developed within the scope of the partnership, which can be developed individually or in cooperation with other companies.
Voyager did not say in its announcement why the partnership was terminated, but given how many drugs in the field failed to get out of the preclinical stage, it shouldn't be too surprising.
through the termination agreement, AbbVie waived some conditional payments that had to be made when the study entered the clinical testing phase.
Voyager's website shows that the company is committed to advancing the application of AAV gene therapy to serious neurological diseases, including Parkinson's disease, Huntington's disease, Friedreich's ataxia, and other serious neurological disorders through innovation and investment in vector engineering and optimization, manufacturing, administration and administration technologies.
the most advanced drug in its research pipeline is VY-AADC, a Gene Therapy based on AAV that is undergoing Phase 2 clinical trials to treat Parkinson's disease, and a gene therapy in collaboration with Neurocrine Biosciences, which aims to convert L-dopatoto into dopamine in patients with Parkinson's disease, possibly registering clinical trials this year.
Source: 1, AbbVie Terminates Alzheimer's Pact with Voyager Therapeutics 2, AbbVie shrugs off $134M cash deals, quitting a neuro r and d pact with Voyager Therapeutics on vectorsized anti-treatments.